For example, for such patients starting statin treatment with a total cholesterol of 4.1 mmol/l, lowering cholesterol to 3.9 mmol/l is clearly not sufficient and a 25% reduction is required. Many people in the United Kingdom are indeed unaware that they have a raised blood pressure and are...
Role of Nonstatin Therapies in Lowering LDL-Cholesterol during Atherosclerotic Cardiovascular Disease Risk Management View Share View All Guidelines Infographics Articles Oral P2Y12inhibitor pre-treatment for percutaneous coronary intervention in non–ST-elevation acute coronary syndromes: evolving notions in ES...
(3.9 mmol/L) or above on maximally tolerated statin dose, consider adding additional LDL-lowering therapy (such as ezetimibe or a proprotein convertase subtilisin/kexin type 9 [PCSK9] inhibitor) after evaluating the potential for further ASCVD risk reduction, drug-specific adverse effects, and ...
the impact of intervention studies in any of the two conditions, to determine the effects on the other one, is difficult to evaluate because medical treatments for LUTS can improve or deteriorate ED and vice versa. For
Consider imaging to evaluate for active disease and/or development of thoracic aortic aneurysm. Consider statin and aspirin therapy whenever indicated If patient is unable to tolerate steroids, consider switching to tocilizumab weekly SC injection.Infection ...
In patients aged 40 to 75 years evaluated for primary ASCVD prevention: Have a clinician–patient risk discussion before starting statin therapy. In nondiabetic patients aged 40 to 75 years and with the following characteristics: LDL-C levels ≥70 mg/dL (≥1.8 mmol/L), at a 10-year ASCVD...
Cholesterol levels and statin use in patients with coronary heart disease treated in primary care settings. Prev Chronic Dis 2005;2 :A05. 38. Ko DT, Hebert PR, Coffey CS, Curtis JP, et al. Adverse effects of beta-blocker therapy for patients with heart failure: a quantitative overview of...
Background: LDL-C reduction with statin therapy has been shown to improve cardiovascular outcomes in patients with coronary artery disease, whether initiat... Cannon,Christopher,P. - 《Circulation》 被引量: 77发表: 2014年 Combination Therapy With Ezetimibe/Simvastatin Versus Statin Monotherapy for Lo...
[1]with a unique focus on the change in paradigm, exposing more patients to statin therapy, and the 4 categories that are deemed to be most likely to benefit from therapy -- one of which is ≥ 7.5% risk over 10 years, which has become the lightning rod for discussions here. Can we ...
Lipid-lowering drug therapy is effective in preventing CVD in high-risk hypertensive patients. In hypertensive patients without CVD, statin was used to lower the LDL-cholesterol level by > 50%, when LDL-cholesterol was ≥130 mg/dL, and its CVD prevention effect is evident [97]. It is...